Manifaxine

Manifaxine (GW-320,659) is a drug developed by GlaxoSmithKline through structural modification of radafaxine, one of the major active metabolites of bupropion. It acts as a norepinephrine-dopamine reuptake inhibitor (NDRI). It was researched for treatment of ADHD and obesity and was shown to be safe, reasonably effective and well tolerated for both applications, but no results have been reported following these initial trials and its current status is unclear.

See also 
 Phenmetrazine
 Radafaxine
 Hydroxybupropion
 G-130
 2-Phenyl-3,6-dimethylmorpholine

References 

Category:Tertiary alcohols
Category:Stimulants
Category:GlaxoSmithKline brands
Category:Norepinephrine-dopamine reuptake inhibitors
Category:Morpholines
Category:Fluoroarenes